Karessa intensifies the development work to prepare for clinical trials within erectile dysfunction
Karessa intensifies the work of developing its unique and patented drug delivery platform This, among other things, by expanding and streamlining the laboratory in Stockholm, where capacity is increased and new analytical equipment is being installed. These measures are important steps in the process of streamlining the final phase of the development and formulation work of the two pharmaceutical projects in Karessa's portfolio.
Karessa is currently working with two projects in the therapeutic area of erectile dysfunction. Both projects are in pre-clinical phase and consists of Karessa's unique and patented drug delivery platform in combination with the active substances Sildenafil and Tadalafil, which are in tablet form in Viagra and Cialis. Karessa's pharmaceuticals will not be administered in tablet form, instead it will be delivered directly into the bloodstream via the oral mucosa via a buccal film. By this way a faster and significantly more reliable effect than today's tablet options. Because the substances are well proven and present on the market, only limited studies are required for Karessa's buccal film products to enter the registration phase.
"During 2015-2016 our focus will be on product development and performance of studies. The fact that we now expand and streamline our laboratory with additional analytical equipment and more capacity means that we are completely in line with our plan and that we are now at the final stage of the formulation work" says Torbjörn Kemper, CEO at Karessa.
Karessa's business model is to combine proven, effective and approved substances with a patented drug delivery platform. The combination creates great benefits, both the patient and Karessa as a company. Patients get a faster and more reliable effect and don't need to plan their life in common. The benefits of Karessa are a faster way to registration and relatively low development risks. The goal is to start clinical studies during 2015.
"The bigger and more efficient lab with new analytical equipment enables us to develop formulations faster and ensure the formulation of the buccal films that will be the base for the clinical studies we will start during 2015", says the company’s development director Erik Mascher.
A multi-billion market
Erectile dysfunction, i.e. an inability to achieve and maintain erection successfully to perform sexual activity affects nearly half of all men over 40 years. The global market is currently valued to approximately $ 4.3 billion.
For more information, please visit karessa.se – or contact:
Torbjörn Kemper
CEO
+46(0) 76 111 39 80
torbjorn.kemper@karessa.se
About Karessa Pharma Holding AB
Karessa Pharma Holding AB develops and commercializes next-generation pharmaceuticals to treat erectile dysfunction. Karessa's concept is based on a patented drug delivery film, which is combined with clinically tested and well proven active substances. The combination enables pharmaceuticals with both a direct and reliable effect. Karessa is listed on Nasdaq First North. www.karessa.se
Tags: